These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
313 related articles for article (PubMed ID: 31020609)
21. FOLFOXIRI in combination with panitumumab as first-line treatment in quadruple wild-type (KRAS, NRAS, HRAS, BRAF) metastatic colorectal cancer patients: a phase II trial by the Gruppo Oncologico Nord Ovest (GONO). Fornaro L; Lonardi S; Masi G; Loupakis F; Bergamo F; Salvatore L; Cremolini C; Schirripa M; Vivaldi C; Aprile G; Zaniboni A; Bracarda S; Fontanini G; Sensi E; Lupi C; Morvillo M; Zagonel V; Falcone A Ann Oncol; 2013 Aug; 24(8):2062-7. PubMed ID: 23666916 [TBL] [Abstract][Full Text] [Related]
22. The efficacy and safety of panitumumab administered concomitantly with FOLFIRI or Irinotecan in second-line therapy for metastatic colorectal cancer: the secondary analysis from STEPP (Skin Toxicity Evaluation Protocol With Panitumumab) by KRAS status. Mitchell EP; Piperdi B; Lacouture ME; Shearer H; Iannotti N; Pillai MV; Xu F; Yassine M Clin Colorectal Cancer; 2011 Dec; 10(4):333-9. PubMed ID: 22000810 [TBL] [Abstract][Full Text] [Related]
23. Phase II study of cetuximab with irinotecan for KRAS wild-type colorectal cancer in Japanese patients. Terazawa T; Nishitani H; Kato K; Hashimoto H; Akiyoshi K; Ito Y; Nakamoto A; Iwasa S; Nakajima TE; Hamaguchi T; Yamada Y; Shimada Y Asia Pac J Clin Oncol; 2017 Apr; 13(2):e132-e137. PubMed ID: 26245851 [TBL] [Abstract][Full Text] [Related]
24. Sotorasib plus Panitumumab in Refractory Colorectal Cancer with Mutated Fakih MG; Salvatore L; Esaki T; Modest DP; Lopez-Bravo DP; Taieb J; Karamouzis MV; Ruiz-Garcia E; Kim TW; Kuboki Y; Meriggi F; Cunningham D; Yeh KH; Chan E; Chao J; Saportas Y; Tran Q; Cremolini C; Pietrantonio F N Engl J Med; 2023 Dec; 389(23):2125-2139. PubMed ID: 37870968 [TBL] [Abstract][Full Text] [Related]
25. Hypomagnesemia is a reliable predictor for efficacy of anti-EGFR monoclonal antibody used in combination with first-line chemotherapy for metastatic colorectal cancer. Fujii H; Iihara H; Suzuki A; Kobayashi R; Matsuhashi N; Takahashi T; Yoshida K; Itoh Y Cancer Chemother Pharmacol; 2016 Jun; 77(6):1209-15. PubMed ID: 27106835 [TBL] [Abstract][Full Text] [Related]
26. The impact of co-expression of wild-type EGFR and its ligands determined by immunohistochemistry for response to treatment with cetuximab in patients with metastatic colorectal cancer. Khelwatty S; Essapen S; Bagwan I; Green M; Seddon A; Modjtahedi H Oncotarget; 2017 Jan; 8(5):7666-7677. PubMed ID: 28032593 [TBL] [Abstract][Full Text] [Related]
27. Efficacy and safety of anti-EGFR monoclonal antibodies combined with different chemotherapy regimens in patients with RAS wild-type metastatic colorectal cancer: A meta-analysis. Sun H; Li Y; Su Y; Wu X; Zhou X; Han J; Li J J Evid Based Med; 2019 Nov; 12(4):300-312. PubMed ID: 31596544 [TBL] [Abstract][Full Text] [Related]
28. Phase II trial of biweekly cetuximab and irinotecan as third-line therapy for pretreated KRAS exon 2 wild-type colorectal cancer. Osumi H; Shinozaki E; Mashima T; Wakatsuki T; Suenaga M; Ichimura T; Ogura M; Ota Y; Nakayama I; Takahari D; Chin K; Miki Y; Yamaguchi K Cancer Sci; 2018 Aug; 109(8):2567-2575. PubMed ID: 29908105 [TBL] [Abstract][Full Text] [Related]
29. A phase I study of selumetinib (AZD6244/ARRY-142866), a MEK1/2 inhibitor, in combination with cetuximab in refractory solid tumors and KRAS mutant colorectal cancer. Deming DA; Cavalcante LL; Lubner SJ; Mulkerin DL; LoConte NK; Eickhoff JC; Kolesar JM; Fioravanti S; Greten TF; Compton K; Doyle AG; Wilding G; Duffy A; Liu G Invest New Drugs; 2016 Apr; 34(2):168-75. PubMed ID: 26666244 [TBL] [Abstract][Full Text] [Related]
30. Phase II Study of Third-Line Panitumumab Rechallenge in Patients with Metastatic Wild-Type KRAS Colorectal Cancer Who Obtained Clinical Benefit from First-Line Panitumumab-Based Chemotherapy: JACCRO CC-09. Tsuji A; Nakamura M; Watanabe T; Manaka D; Matsuoka H; Kataoka M; Takeuchi M; Ichikawa W; Fujii M Target Oncol; 2021 Nov; 16(6):753-760. PubMed ID: 34718946 [TBL] [Abstract][Full Text] [Related]
31. Multicenter Phase II study of cetuximab plus irinotecan in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin and fluoropyrimidines. Tahara M; Shirao K; Boku N; Yamaguchi K; Komatsu Y; Inaba Y; Arai T; Mizunuma N; Satoh T; Takiuchi H; Nishina T; Sakata Y Jpn J Clin Oncol; 2008 Nov; 38(11):762-9. PubMed ID: 18836202 [TBL] [Abstract][Full Text] [Related]
32. A randomised, open-label phase II trial of afatinib versus cetuximab in patients with metastatic colorectal cancer. Hickish T; Cassidy J; Propper D; Chau I; Falk S; Ford H; Iveson T; Braun M; Potter V; Macpherson IR; Finnigan H; Lee C; Jones H; Harrison M Eur J Cancer; 2014 Dec; 50(18):3136-44. PubMed ID: 25441408 [TBL] [Abstract][Full Text] [Related]
33. Multicenter Phase II study of FOLFOX or biweekly XELOX and Erbitux (cetuximab) as first-line therapy in patients with wild-type KRAS/BRAF metastatic colorectal cancer: The FLEET study. Soda H; Maeda H; Hasegawa J; Takahashi T; Hazama S; Fukunaga M; Kono E; Kotaka M; Sakamoto J; Nagata N; Oba K; Mishima H BMC Cancer; 2015 Oct; 15():695. PubMed ID: 26467662 [TBL] [Abstract][Full Text] [Related]
35. Dual Inhibition of EGFR and VEGF in Heavily Pretreated Patients with Metastatic Colorectal Cancer. Larsen FO; Markussen A; Nielsen D; Colville-Ebeling B; Riis LB; Jensen BV Oncology; 2017; 93(3):191-196. PubMed ID: 28531891 [TBL] [Abstract][Full Text] [Related]
36. Cetuximab and irinotecan as third-line therapy in advanced colorectal cancer patients: a single centre phase II trial. Vincenzi B; Santini D; Rabitti C; Coppola R; Beomonte Zobel B; Trodella L; Tonini G Br J Cancer; 2006 Mar; 94(6):792-7. PubMed ID: 16508634 [TBL] [Abstract][Full Text] [Related]
37. Multicenter Single-Arm, Two-Stage Phase 2 Study of Panitumumab in Patients With Cetuximab-Refractory Metastatic Colorectal Cancer: The PACER Trial. Piccirillo MC; Avallone A; Carlomagno C; Maiello E; Rosati G; Alabiso O; Nasti G; De Placido S; Latiano TP; Bilancia D; Ottaiano A; De Stefano A; Romano C; Silvestro L; Nappi A; Cassata A; Giordano P; Iaffaioli RV; Normanno N; Perrone F; Daniele B Clin Colorectal Cancer; 2020 Dec; 19(4):270-276. PubMed ID: 32631788 [TBL] [Abstract][Full Text] [Related]
38. Final Analysis of Outcomes and RAS/BRAF Status in a Randomized Phase 3 Study of Panitumumab and Best Supportive Care in Chemorefractory Wild Type KRAS Metastatic Colorectal Cancer. Kim TW; Elme A; Park JO; Udrea AA; Kim SY; Ahn JB; Valencia RV; Krishnan S; Manojlovic N; Guan X; Lofton-Day C; Jung AS; Vrdoljak E Clin Colorectal Cancer; 2018 Sep; 17(3):206-214. PubMed ID: 29703606 [TBL] [Abstract][Full Text] [Related]
39. EPHA2 Is a Predictive Biomarker of Resistance and a Potential Therapeutic Target for Improving Antiepidermal Growth Factor Receptor Therapy in Colorectal Cancer. Martini G; Cardone C; Vitiello PP; Belli V; Napolitano S; Troiani T; Ciardiello D; Della Corte CM; Morgillo F; Matrone N; Sforza V; Papaccio G; Desiderio V; Paul MC; Moreno-Viedma V; Normanno N; Rachiglio AM; Tirino V; Maiello E; Latiano TP; Rizzi D; Signoriello G; Sibilia M; Ciardiello F; Martinelli E Mol Cancer Ther; 2019 Apr; 18(4):845-855. PubMed ID: 30824612 [TBL] [Abstract][Full Text] [Related]
40. Use of a High-Throughput Genotyping Platform (OncoMap) for Kim D; Hong YS; Kim JE; Kim KP; Lee JL; Chun SM; Kim J; Jang SJ; Kim TW Cancer Res Treat; 2017 Jan; 49(1):37-43. PubMed ID: 27121720 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]